• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilar Articles for the Week of February 13

Video

Here are the top 5 biosimilar articles for the week of February 13, 2023.

Hi, I’m Justina Petrullo for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of February 13th, 2023.

Number 5: Amgen’s Amjevita (adalimumab-atto) has officially entered the US market, making it the first of potentially 10 biosimilars referencing Humira to launch in 2023.

Number 4: IQVIA’s Biosimilars in the United States 2023-2027 report found that while the US biologics market has grown 12.5% annually over the last 5 years, spending on biosimilars is growing and is expected to reach $129 billion by 2027.

Number 3: Sandoz announced that the FDA has accepted the company’s biologics license application (BLA) for its denosumab biosimilar candidate for review.

Number 2: Formycon shared positive data on its Eylea (aflibercept) biosimilar; Sandoz received a thumbs up from the European Union’s Committee for Medicinal Products for Human Use (CHMP); and Shanghai Henlius Biotech began a phase 1 study for its daratumumab biosimilar candidate.

Number 1: Sonia T. Oskouei, PharmD, vice president of biosimilars and specialty at Sandoz, foreshadowed how the US market introduction of adalimumab biosimilars could influence future biosimilar entrances and discussed why educational efforts need to be tailored to different specialties and stakeholders.

To read all of these articles and more, visit centerforbiosimilars.com.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.